Study design and participants
sarcoma, tumors
TUMORS, SARCOMA, RHABDOMYOSARCOMA, EWING SARCOMA, PATHOLOGY
In this single-arm phase II trial, adult patients (aged ≥18 years) bearing advanced and measurable tumors according to RECIST criteria with a diagnosis of any sarcoma subtype (excluding DD-LPS, rhabdomyosarcoma, and Ewing sarcoma) that had progressed in the last 6 months, were screened to participate at 13 tertiary Spanish hospitals with expertise in sarcoma care and research. Additional inclusion criteria were central pathology confirmation of sarcoma, overexpression of 